GC Genome Launches 'Naite' Telomere Test, and More

GC Genome has introduced the 'Naite' test, a diagnostic tool designed to measure biological age and aging rates by analyzing telomere length. This development coincides with several major advancements in the Korean healthcare sector, including Seoul National University Hospital's move toward clinical trials for a new CAR-T therapy and Macrogen’s large-scale genetic identification project for the Ministry of National Defense. These initiatives reflect a growing trend in the biotech industry toward personalized diagnostics, advanced immunotherapy, and the application of genomic data for public service and specialized hospital care.

GC Genome’s new 'Naite' test utilizes telomere analysis to provide patients with insights into their biological age compared to their chronological peers. Telomeres are repetitive genetic sequences at the ends of chromosomes that protect against damage and fusion, and their length is scientifically linked to human aging and lifespan. By measuring these sequences, the Naite test identifies the specific rate of aging, offering a data-driven approach to longevity and wellness management within the diagnostic market.

In the field of oncology, Seoul National University Hospital has formally submitted a clinical trial plan to the Ministry of Health and Welfare for its proprietary CAR-T (Chimeric Antigen Receptor T-cell) therapy. This advanced immunotherapy is designed to program immune cells to specifically target and eliminate cancer cells. Pending government approval, the hospital intends to transition into direct patient administration, marking a significant step forward in domestic access to next-generation cancer treatments.

Simultaneously, Macrogen has secured a 1.2 billion won contract with the Ministry of National Defense Agency for KIA Recovery & Identification (MAKRI) to conduct genetic testing for approximately 7,000 family members of Korean War casualties. This six-month project, running from April to October, highlights the expanding role of genomic companies in large-scale national identification efforts. Additionally, Hallym University Kangnam Sacred Heart Hospital is partnering with healthcare firms NeoAble and Able Designs to develop a 'smart hospital' infrastructure focused on the prevention of pressure sores, aiming to reduce patient discomfort through technological integration.